H.C. Wainwright reiterates Legend Biotech stock rating at buy

Legend Biotech is highlighted as undervalued, with H.C. Wainwright reiterating a Buy rating and $65 PT despite the stock trading at $21.75 (vs $4.21B market cap) and analysts’ PTs spanning $24 to $78. Clinical read-through for AbbVie’s CERVINO Phase 3 supports etentamig efficacy (74.0% overall response vs 45.7% standard therapy; 60% reduction in progression/death risk), though Wainwright cautions it may pressure repeated-dose BCMA bispecifics. Legend also delivered strong fundamentals—Q2 adjusted EPS $0.16 and revenue $387.5M (+52% YoY)—but Oppenheimer downgraded it to Perform from Outperform and cut its PT to $40 on concerns about weaker M&A prospects and internal challenges.

Analysis

This is less about one positive readout and more about a category-ratings event for BCMA. If AbbVie files on the asset, the market starts discounting a new late-line entrant that can pressure the lower-quality repeated-dose bispecifics first; that matters because the group’s valuation has been built on durability assumptions, not just response rates. The knock-on is that differentiated cell-therapy franchises such as LEGN’s partner asset become comparatively more defensible if investors conclude the tradeoff is efficacy without a clear convenience advantage.

The market is likely to overreact on the first headline and then reprice again at the detailed data presentation. The real swing factor is not ORR; it is median PFS, duration of response, and whether safety/administration burden narrows the adoption gap enough to matter commercially. A filing can create a 1-3 month sentiment tailwind for ABBV, but if the fuller dataset fails to extend the duration curve, the move should fade.

Contrarian read: consensus may be underestimating how much this helps the incumbent CAR-T ecosystem by validating BCMA demand rather than “killing” it. LEGN does not need this exact program to fail; it only needs the street to stop assuming every incremental BCMA advance is immediately share-taking. For MRNA, oncology progress remains a platform proof point, but it is still a 6-18 month story unless the data consistently translate into late-stage pipeline value.

Key Decisions for Investors

• Add ABBV on a tactical basis only into the filing/IMS window; treat it as a 1-3 month event trade, with thesis broken if detailed PFS/DOR underwhelm or filing timing slips.
• Use LEGN as a relative-strength long on any post-data pullback; 3-6 month upside comes from the market assigning higher terminal CARVYKTI durability, with risk capped if uptake inflects slower than expected in 2L-4L.
• If you want a cleaner hedge, pair long LEGN against a broad biotech beta basket (XBI) into the catalyst window; the thesis is that this read-through is more idiosyncratically favorable to CAR-T than to the average biotech name.
• Set an alert for the IMS presentation: if median PFS and duration of response are strong, stay long ABBV/LEGN into the next leg; if those metrics disappoint, fade the move and expect the competitive impact to remain mostly narrative, not financial.